DaVita (NYSE:DVA – Get Free Report) will be releasing its earnings data after the market closes on Thursday, May 2nd. Analysts expect DaVita to post earnings of $1.96 per share for the quarter. DaVita has set its FY24 guidance at $8.70-9.80 EPS and its FY 2024 guidance at 8.700-9.800 EPS.Investors interested in listening to the company’s conference call can do so using this link.
DaVita (NYSE:DVA – Get Free Report) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.53 by $0.34. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The firm had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.01 billion. During the same quarter last year, the firm earned $1.11 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, analysts expect DaVita to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.
DaVita Stock Performance
NYSE:DVA opened at $139.01 on Wednesday. The company’s 50-day moving average is $132.44 and its two-hundred day moving average is $111.30. The firm has a market capitalization of $12.19 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 1.19 and a beta of 1.04. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. DaVita has a 1-year low of $71.51 and a 1-year high of $141.54.
Wall Street Analysts Forecast Growth
Get Our Latest Research Report on DVA
Insider Activity
In related news, insider James O. Hearty sold 26,164 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the sale, the insider now directly owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, COO Michael David Staffieri sold 29,488 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $119.81, for a total transaction of $3,532,957.28. Following the sale, the chief operating officer now directly owns 37,687 shares in the company, valued at $4,515,279.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James O. Hearty sold 26,164 shares of DaVita stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the transaction, the insider now owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The disclosure for this sale can be found here. Over the last quarter, insiders sold 134,540 shares of company stock valued at $16,551,071. 1.40% of the stock is currently owned by company insiders.
About DaVita
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also
- Five stocks we like better than DaVita
- Canada Bond Market Holiday: How to Invest and Trade
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Hilton Demonstrates Asset Light is Right for Investors
- 5 Top Rated Dividend Stocks to Consider
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.